BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Empagliflozin: Additional Phase III data

Data from 899 treatment-naïve Type II diabetics with an HbA1c of <=10% in the double-blind, international Phase III Study 1245.20 showed that once-daily empagliflozin led to placebo-adjusted reductions in HbA1c from baseline to week 24, the primary endpoint, of 0.74% in the 10 mg dose arm and 0.85% in the 25 mg dose arm (p<0.001 for both). The active comparator once-daily 100 mg sitagliptin led to a placebo-adjusted reduction in HbA1c from baseline to week 24 of 0.73% (p<0.001). The partners said sitagliptin was used...

Read the full 403 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >